28 articles for Z Fu
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
Amgen
Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
Amgen
Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
Daiichi Sankyo
Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
Amgen
Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction.
Amgen
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.
Amgen
Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.
Amgen
Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis.
Sichuan University
Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.
Amgen
Fragment growth-based discovery of novel TNIK inhibitors for the treatment of colorectal cancer.
Sichuan University
Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis.
China Pharmaceutical University
Discovery and optimization of selective RET inhibitors via scaffold hopping.
Guangzhou Baiyunshan Pharmaceutical Holdings
Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
Shandong University
Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394.
Amgen
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties.
Amgen
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
Merck Sharp & Dohme
Structure of REV-ERBß ligand-binding domain bound to a porphyrin antagonist.
The Scripps Research Institute
The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
Harvard Neurodiscovery Center
New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.
Universidade De Evora
Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines
City of Hope